Australia markets closed

Vaccitech plc (VACC)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
2.9500-0.1000 (-3.28%)
At close: 04:00PM EST
2.8900 -0.06 (-2.03%)
After hours: 05:24PM EST

Vaccitech plc

The SchrOedinger Building
Heatley Road The Oxford Science Park
Oxford OX4 4GE
United Kingdom
44 1865 818 808

Full-time employees72

Key executives

NameTitlePayExercisedYear born
Mr. William J. Enright MBACEO & Director754.28kN/A1963
Dr. Margaret Marshall M.D.Chief Medical Officer547.97kN/A1957
Ms. Sarah GilbertCo-FounderN/AN/AN/A
Mr. Adrian Hill Ph.D.Co-Founder & Scientific AdvisorN/AN/AN/A
Ms. Gemma BrownChief Financial OfficerN/AN/AN/A
Mr. Chris EllisChief Operating OfficerN/AN/A1960
Dr. Thomas George Evans M.D.Chief Scientific OfficerN/AN/A1955
Mr. Graham GriffithsChief Bus. OfficerN/AN/A1979
Ms. Elizabeth Eagling-Vose M.B.A.Head of Clinical OperationsN/AN/AN/A
Bernie McDonaldHead of IPN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.

Corporate governance

Vaccitech plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.